Brett Lovejoy advises clients on many aspects of intellectual property ownership and protection. Central to his practice is helping businesses create patent portfolios. This includes writing, prosecuting, and enforcing patents in the United States, while coordinating clients’ worldwide patent protection efforts. Brett also provides strategic counseling to his clients, conducts IP due diligence, and offers IP opinions.
Brett has experience with writing and prosecuting patents that encompass computer-implemented technology, artificial intelligence, bioinformatics, diagnostics, digital health applications, quantum computation, medical and consumer devices, chemistry, biochemistry, renewable energy, and electrical circuit design. Third parties have purchased many of the patents written by Brett Lovejoy, and others have been successfully enforced through litigation, or used as a basis for successful corporate fund raising.
As a postdoctoral fellow at UCLA, Brett authored software programs in various programming languages. He also worked as a research scientist at GlaxoSmithKline and Roche. He has served as first author of many peer-reviewed articles, including a Science article describing the X-ray crystal structure of a GlaxoSmithKline inhibitor bound to the active site of collagenase, and a Science report describing the X-ray crystal structure of a synthetic designer protein developed in a collaboration between Dr. David Eisenberg of UCLA and DuPont.
Santa Clara University School of Law, 2000, J.D.
University of California, Los Angeles, 1992, Ph.D. (Molecular Biology)
University of California, Santa Cruz, 1988, B.A. (Chemistry), With Honors